Results from the Fame II study comparing St. Jude Medical‘s (NYSE:STJ) PressureWire fractional flow reserve device with optimal medical care show that FFR-guided coronary interventions are more cost-effective, sending STJ shares up nearly 2% today on Wall Street.
Transcatheter Cardiovascular Therapeutics symposium (TCT)
TCT 2012: Drug-eluting and semi-resorbable stents hold their own
Stent makers came out in force for the Transcatheter Cardiovascular Therapeutics meeting in Miami this week, touting results of clinical studies of next-generation drug-eluting stents and new designs with bioresorbable polymers.
Stent wars at TCT 2012: Drug-eluting stents maintain lead over bare-metal
With new and next-generation stents gaining ground over their forebears, the stent wars don’t look to be letting up anytime soon.
The battle continued at the Transcatheter Cardiovascular Therapeutics meeting this week, where pooled results from a pair of studies further affirmed that next-generation drug-eluting stents demonstrate better safety and efficiency at 1 year compared to bare-metal stents.
Researchers combined data from the Examination and Comfortable AMI studies, which comprised a total of more than 2,600 patients, to look for larger trends in the DES vs. BMS battle.
TCT 2012: New trials and positive results for cardiac implants
Stentys lands FDA nod to launch 1st U.S. trial with novel Self-Apposing stent
Stent maker Stentys SA (EPA:STNT) won FDA investigational device exemption to launch its 1st U.S. clinical trial of its Self-Apposing stent that it hopes to use in support of a premarketing approval bid.
The announcement was made as the company, in a separate release, unveiled interim results of its Apposition III trial during the Transcatheter Cardiovascular Therapeutics conference in Miami this week.
TCT2012: Medtronic’s CoreValve system shows high survival rate
Minneapolis health giant Medtronic (NYSE:MDT) unveiled new findings from its CoreValve Advance study, showing a 1-year survival rate of 82.1% and improved health-rated quality of life at 1 and 6 months.
Medtronic’s CoreValve device is a self-expanding heart valve prosthetic that can be delivered via catheter rather than through surgery.
MassDevice.com +7 | Strkyer launches lawsuits, Zimmers acquires Xtrafix, Fresenius sues supplier, FDA seeks reclass comments, Over-stenting doc, MDT vs. ABT, GOP grills Shuren
Say hello to MassDevice +7, a bite-sized view of the top seven med-tech stories of the week. This latest feature of MassDevice.com’s coverage highlights our seven biggest and most influential stories from the week’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
If you read nothing else this weekend, make sure you’re still in the know with MassDevice +7.
Volcano touts “excellent diagnostic efficiency” for drug-free ischemia detection system
Volcano Corp.’s (NSDQ:VOLC) instant wave-Free Ratio coronary lesion detector proved highly effective at diagnosing coronary lesions, according to the results of the company’s Advise trials.
The instant wave-Free Ratio (iFR) system, under investigational device exemption in the U.S., aims to provide a pharmaceutical-free alternative to the gold standard fractional flow reserve (FFR) method for assessing narrowed blood vessels.
TCT 2011: Medtronic’s Resolute DES just as effective as Abbott’s market-leading Xience V
TCT 2011: Benefits for Edwards’ valve patients increase at the two-year mark
Patients treated with Edwards Lifesciences’ (NYSE:EW) Sapien heart valve had a lower mortality rate and spent less time in hospitals at the two-year mark, according to the data released at this year’s Transcatheter Cardiovascular Therapeutics symposium.
The Partner trial consisted of patients with aortic stenosis, randomized to receive a Sapien valve with transcatheter aortic valve replacement surgery or traditional open-heart surgery.
TCT 2011: Three ways to spur U.S. medical innovation
The U.S. medical device arena is in danger of ceding the throne to countries with friendlier regulatory environments but the system is not irreparable, Dr. Martin Leon said during a lecture at this week’s Transcatheter Cardiovascular Therapeutics symposium in San Francisco.